stockrow
Friday 6 November 2026
Export BHVN’s income statement to Excel — free account
Biohaven Ltd.
BHVN Healthcare Biotechnology
- EPS
- +47.8%
- Free cash flow
- +26.6%
- Total debt
- −1.48%
Quarter to September 2026, against a year earlier
14.41
0.51
+3.67%
Follow BHVN
Alert me
Biohaven Ltd. (BHVN) EPS (diluted)
Biohaven Ltd.'s EPS (diluted) for fiscal 2025 was −$6.86, compared with −$9.28 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$3.86. Over the past ten years it has ranged from −$12.75 (fiscal 2022) to −$0.91 (fiscal 2015); the current reading is higher than 36% of that period. Biohaven Ltd. ranks 414th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$6.86 | — |
| FY2024 | −$9.28 | — |
| FY2023 | −$5.73 | — |
| FY2022 | −$12.75 | — |
| FY2021 | −$5.43 | — |
| FY2020 | −$3.01 | — |
| FY2019 | −$10.91 | — |
| FY2018 | −$6.15 | — |
| FY2017 | −$5.00 | — |
| FY2016 | −$5.04 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.86 | — |
| Jun 2026 | −$0.91 | — |
| Mar 2026 | −$0.88 | — |
| Dec 2025 | −$1.21 | — |
| 39 more quarters | Free account |
Against its own ten years
Low −$12.75
High −$0.91
Ten-year median
−$5.73
Current reading's percentile
36
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $2.29 |
| ADMA ADMA Biologics Inc compare | $0.77 |
| VCEL Vericel Corporation compare | $0.65 |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$0.29 |
| IMNM Immunome, Inc. compare | −$2.53 |
| BHVN Biohaven Ltd. | −$3.86 |
| CLDX Celldex Therapeutics, Inc. compare | −$4.35 |
| PVLA Palvella Therapeutics, Inc. compare | −$4.83 |
| VERA Vera Therapeutics, Inc. compare | −$5.86 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item